HO-AAVPA

HO-AAVPA is a small-molecule derivative of valproic acid chemically known as N-(2-hydroxyphenyl)-2-propylpentanamide. It is a histone deacetylase (HDAC) inhibitor, with preclinical studies demonstrating selective inhibition of HDAC1, HDAC6, and HDAC8, though with the most potent activity against HDAC1. Designed to improve upon the pharmacological profile of valproic acid, HO-AAVPA exhibits enhanced antiproliferative effects in cancer cell lines, including breast cancer (both luminal and triple-negative subtypes) and cervical cancer cells, compared to VPA. Proposed mechanisms include HDAC inhibition leading to epigenetic modulation, downregulation of G protein-coupled estrogen receptor (GPER) expression, induction of apoptosis, S-phase cell cycle arrest, increased ROS production, and HMGB1 translocation. Its pharmacological investigation focuses on malignancies, particularly breast cancer, and it is the subject of ongoing preclinical research for its anticancer potential[1][2][3][4][5].

Other names

N-(2-hydroxyphenyl)-2-propylpentanamide